Last reviewed · How we verify
Foquest
Foquest, marketed by JPM van Stralen Medicine Professional, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its established patient base and brand recognition. The primary risk is the patent expiration in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Foquest |
|---|---|
| Sponsor | JPM van Stralen Medicine Professional |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity (PHASE4)
- Evaluation of the Effect Foquest® on Sleep in Children Aged 6-12 With ADHD (PHASE4)
- Real World Evidence of the Efficacy and Safety of FOQUEST (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Foquest CI brief — competitive landscape report
- Foquest updates RSS · CI watch RSS
- JPM van Stralen Medicine Professional portfolio CI